Land: Europese Unie
Taal: Engels
Bron: EMA (European Medicines Agency)
clopidogrel
Acino Pharma GmbH
B01AC04
clopidogrel
Antithrombotic agents
Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.For further information please refer to section 5.1.
Revision: 1
Withdrawn
2009-09-21
B. PACKAGE LEAFLET 21 Medicinal product no longer authorised PACKAGE LEAFLET: INFORMATION FOR THE USER CLOPIDOGREL ACINO PHARMA GMBH 75 MG FILM-COATED TABLETS Clopidogrel READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist, IN THIS LEAFLET : 1. What Clopidogrel Acino Pharma GmbH is and what it is used for 2. Before you take Clopidogrel Acino Pharma GmbH 3. How to take Clopidogrel Acino Pharma GmbH 4. Possible side effects 5. How to store Clopidogrel Acino Pharma GmbH 6. Further information 1. WHAT CLOPIDOGREL ACINO PHARMA GMBH IS AND WHAT IT IS USED FOR Clopidogrel Acino Pharma GmbH contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products. Platelets (so-called thrombocytes) are very small structures, which clump together during blood clotting. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis). Clopidogrel Acino Pharma GmbH is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). You have been prescribed Clopidogrel Acino Pharma GmbH to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions) 2. BEFORE YOU TAKE CLOPIDOGREL A Lees het volledige document
_ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 Medicinal product no longer authorised 1. NAME OF THE MEDICINAL PRODUCT Clopidogrel Acino Pharma GmbH 75 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as besilate). Excipients: each film-coated tablet contains 3.80 mg of hydrogenated castor oil. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White to off-white, marbled, round and biconvex film-coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For further information please refer to section 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and elderly Clopidogrel should be given as a single daily dose of 75 mg. If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. - For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). Hepatic impairment Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4). 2 Medicinal product no longer authorised Method of administration For oral use It may be given with or without food. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients. Severe hepatic impairment. Active pathological bleeding such as peptic ulcer or intracranial haemorr Lees het volledige document